Tscan Therapeutics (TCRX) - News Mentions

Sign up to add (TCRX) to your portfolio and access more historical data.

0 100%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 0%
Gilead Sciences
Gilead Sciences
GILD		 0 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 1 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 1 0%
TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an investment
December 27
Stifel Financial Corp Has $494,000 Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)
December 27
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing
December 25
Wedbush Reiterates Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)
December 23
XTX Topco Ltd Takes $112,000 Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)
December 22
TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at HC Wainwright
December 12
**TScan Therapeutics (NASDAQ: TCRX) Issues Report on Updated Phase 1 Trial Data for ALLOHA Program**On December 9, 2024, TScan Therapeutics, Inc. released a comprehensive report on the latest developments surrounding its ALLOHA ™ Phase 1 trial, focus
December 11
Lifesci Capital Has Pessimistic View of TCRX FY2024 Earnings
November 16
Research Analysts Set Expectations for TCRX FY2028 Earnings
November 15
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
November 11
TScan Therapeutics’ (TCRX) “Buy” Rating Reiterated at Needham & Company LLC
November 8
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
November 6
TScan Therapeutics (TCRX) Gets a Buy from Barclays
October 29
Comparing ProKidney (NASDAQ:PROK) and TScan Therapeutics (NASDAQ:TCRX)
October 28
Renaissance Technologies LLC Has $468,000 Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)
October 11
Marshall Wace LLP Boosts Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)
October 6

Month over Month

Est. daily news mentions.

Nov 2024 0
Oct 2024 0
Sep 2024 0

How often is Tscan Therapeutics mentioned in the news?

Tscan Therapeutics was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Tscan Therapeutics performing compared to its industry peers?

Tscan Therapeutics underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Tscan Therapeutics in the last month?

There has been no significant change in the number of news mentions for Tscan Therapeutics' compared to the last month.

Why is it important to track news mentions for Tscan Therapeutics?

By monitoring mentions in the news for Tscan Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Tscan Therapeutics, ultimately improving their investment strategies.

Sign up and get more insights on Tscan Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact